The Cocktail Report (sound really smart around your friends):
Two new studies presented at the SCAI 2026 Scientific Sessions in Montreal (April 23-25, 2026) found that tirzepatide (the active ingredient in Mounjaro and Zepbound) dramatically reduced cardiovascular risk in patients undergoing major heart procedures.
In the first study, patients with type 2 diabetes who took tirzepatide at the time of a PCI procedure (percutaneous coronary intervention, a procedure to open blocked arteries, also called angioplasty) had a 54% lower risk of major adverse cardiovascular events, including heart attack, compared to patients on an older GLP-1 drug within just one month.
At one year, the benefits expanded: reductions in heart attack and heart failure held, and additional reductions appeared in mortality, stroke, and cardiac arrest.
In the second study, patients with obesity who underwent TAVR (transcatheter aortic valve replacement, a minimally invasive procedure to replace a faulty heart valve) and did NOT receive tirzepatide had a 54% higher risk of hospitalization for acute heart failure and experienced major adverse cardiovascular events 44% more frequently.
A separate Cleveland Clinic analysis of the landmark SURPASS-CVOT trial (13,000+ participants, nearly 4 years of follow-up) found tirzepatide reduced a broad six-component composite of heart and kidney events by 16% compared to dulaglutide, another GLP-1 drug, a statistically significant result.
A network meta-analysis published in Cardiovascular Diabetology (Feb 2026) confirmed tirzepatide significantly reduced MACE, cardiovascular mortality, all-cause mortality, heart attack, and stroke compared to placebo.
Tirzepatide works by activating both GLP-1 and GIP hormone receptors (two gut hormones released after eating), making it the only dual incretin drug in its class.
Experts believe the cardiovascular benefits come from multiple pathways: weight loss, blood sugar control, blood pressure reduction, lower cholesterol, reduced inflammation, and possibly direct protective effects on heart muscle and blood vessels.
Neither study has yet been published in a peer-reviewed journal; both were conference presentations from database analyses, meaning they require follow-up validation.
Tirzepatide is currently FDA-approved as Mounjaro (for type 2 diabetes) and Zepbound (for obesity), but not yet approved for a cardiovascular indication.
If you or someone you know takes Mounjaro or Zepbound, or has been prescribed any GLP-1 medication, this new research changes what that prescription actually means.
Two studies presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2026 conference examined what happens to high-risk cardiac patients who also take tirzepatide. Both found striking reductions in serious cardiovascular events, on top of the drug's already established weight loss effects.
The first study, from Cook County Hospital researchers in Chicago, reviewed 1,281 patients with type 2 diabetes undergoing PCI (percutaneous coronary intervention, a catheter procedure to open blocked coronary arteries) who were on either tirzepatide or dulaglutide, an older GLP-1 drug. Those on tirzepatide had a 54% lower one-month risk of MACE (major adverse cardiovascular events, the composite of heart attack, stroke, and cardiovascular death).
The death risk at one year was 62% lower among tirzepatide users, with additional reductions in heart failure, stroke, and cardiac arrest also emerging over that period.
The second study, from the University of Texas Medical Branch, examined patients with obesity undergoing TAVR (transcatheter aortic valve replacement, a procedure used when the heart's aortic valve is severely narrowed). Patients who did not receive tirzepatide faced a 54% higher risk of hospitalization for acute heart failure and experienced MACE 44% more frequently than those who did.
These findings land alongside already-published trial data. The SURPASS-CVOT trial (13,000 participants, four-year follow-up) showed tirzepatide reduced a six-endpoint composite of heart and kidney events by 16% compared to dulaglutide, and a network meta-analysis in Cardiovascular Diabetology confirmed significant MACE, mortality, heart attack, and stroke reductions versus placebo.
Cardiologists not involved in the studies say the results align with what the field is increasingly seeing, though they urge caution. The 54% figure is likely amplified by patient selection factors and socioeconomic differences that database analyses cannot fully control for.
Prospective randomized trials are the next step.
What is not in dispute is the mechanism: tirzepatide targets two gut hormones simultaneously (GLP-1 and GIP, both released after eating), producing greater weight loss and metabolic improvement than single-target GLP-1 drugs. Those downstream effects on blood sugar, blood pressure, cholesterol, inflammation, and liver fat all reduce cardiovascular risk through well-understood pathways.
Why Should You Care?
Heart disease is the leading cause of death in the United States, and cardiovascular risk is one of the central concerns in longevity medicine. A drug already prescribed to tens of millions of people may be doing double duty: managing weight and metabolism while simultaneously protecting the heart.
That shifts the way doctors and patients should think about these prescriptions. They may not just be about the number on the scale.
Citations:
Healthline. "Mounjaro, Zepbound Lowers Risk of Cardiovascular Death by 62%." April 25, 2026. https://www.healthline.com/health-news/tirzepatide-reduces-risk-major-cardiovascular-events
Cleveland Clinic Newsroom. "Tirzepatide Associated with Lower Risk of Heart and Kidney Damage Compared to Dulaglutide." March 28, 2026. https://newsroom.clevelandclinic.org/2026/03/28/tirzepatide-associated-with-lower-risk-of-heart-and-kidney-damage-compared-to-dulaglutide-in-patients-with-type-2-diabetes-and-cardiovascular-disease
UTMB News. "GLP-1-Based Drug Tirzepatide Reduces Heart Risk in High-Risk Patients." April 23, 2026. https://www.utmb.edu/news/article/utmb-news/2026/04/23/glp-1-based-drug-tirzepatide-reduces-heart-risk-in-high-risk-patients
PubMed / Cardiovascular Diabetology. "Comparative efficacy of tirzepatide and GLP-1 receptor agonists on cardiovascular outcomes." Feb 27, 2026. https://pubmed.ncbi.nlm.nih.gov/41761267/
